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Tuberculosis (TB) is a re-emerging disease that is considered a major human health
priority as well as an important disease of livestock. TB is also a zoonosis, andMycobac-
terium tuberculosis and M. bovis, the human and bovine causative agents, respectively,
are very closely related. Protection against TB is essentially achieved through vaccina-
tion with the Bacille Calmetle-Guerin (BCG) strain of M. bovis. Protection is, however,
incomplete, and novel improved vaccines are currently under investigation. Production
of protective antigens in transgenic plants, or “pharming,” is a promising emerging
approach, and a zoonosis-like TB is a good model for investigating the potential of
this approach. Pharma-Planta, a European Commission-funded project and consor-
tium, was set up to address this topic, within which a component is aimed at assessing
the production efficacy and stability of the TB antigens in different compartments of
the plant cell. This article is meant to introduce this promising approach for veterinary
medicine by describing the ongoing project and its specific genetic engineering strategy.
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Introduction
Tuberculosis (TB) is a re-emerging disease
which infects one-third of the world popu-
lation, resulting annually in 9 million new
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cases and 3 million deaths.1,2 TB is also an
important animal disease resulting in signif-
icant losses. Protection against TB is essen-
tially achieved through vaccination with the
Bacille Calmetle-Guerin (BCG) strain of My-
cobacterium bovis. However, BCG confers lim-
ited protection,1 interferes with skin tests for
diagnostic and epidemiological survey,3 and
is highly susceptible to environmental con-
straints, such as cold chain interruption. Novel
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vaccines are thus currently under investiga-
tion. Production of protective antigens in trans-
genic plants is one of these exploratory ap-
proaches. Plant production of pharmaceuticals
is an emerging field with high efficiency in pro-
duction of antibodies.4 However, production of
antigens is more delicate owing to lower ex-
pression levels, influence of cell compartments
in stability, and presence of plant contami-
nants, all resulting in low purification yields.
This article summarizes genetic engineering
approaches specifically designed to investigate
the influence of each cell compartment in
the production efficiency of an antigen. This
project is a part of the European Commission-
funded Pharma-Planta project, aimed at de-
veloping and mastering production of pharma-
ceuticals in plants and focusing on TB as a
model.
The Pharma-Planta Project
The Pharma-Planta project is a consortium
of 39 principal scientists from academic and
industrial institutions in Europe and South
Africa. Pharma-Planta is funded by the EC
and aims to build a plant-based production
platform for pharmaceuticals in Europe and to
enter the first candidate pharmaceuticals into
human clinical trials. Plants have enormous
potential for the production of recombinant
pharmaceutical proteins as they are inexpen-
sive, versatile, and amenable to rapid and eco-
nomical scale-up. The project addresses phar-
maceuticals for the prevention of HIV, rabies,
TB, and diabetes that remain significant health
problems both in Europe and the developing
world.
A Promising Approach for Future
Generations of Vaccines
Production of pharmaceuticals in plants is
definitely a promising approach and is already
capable of delivering large amounts of high-
purity antibodies at a very competitive cost.
The production of specific high-added value,
such as lipase or insulin, is also successfully
implemented.5,6 However, production of anti-
gens, and thus vaccines, is still in the ex-
ploratory track owing to high variability of ex-
pression efficiency, depending both upon cell
compartments and foreign protein. The purifi-
cation of antigens from plants is the first step
toward the production of edible vaccines in
plants, which could definitely lower the cost of
vaccination for many diseases. This approach
is of particular interest in veterinary medicine
considering the cost of vaccination with respect
to limited added value of the products. How-
ever, there is as yet no way to predict the pro-
duction efficiency of antigens in plants, and,
should this approach prove valuable for vac-
cine production, there is currently a need for
comprehensive investigation on the potential
of each cell compartment for the production of
antigens.
A Specific Genetic Engineering
Approach
To investigate the respective influence of
each cell compartment on protein stability,
production, and recovery efficiency, a single
transgene cassette was expressed in Nicotiana
tabaccum var. petit havanna, a variety of tobacco
that was selected for comparative expression
analysis, and the following cell compartments
of the same transgene cassette: chloroplast, cy-
toplasm, cytoplasm anchored to the cytosolic
side of the reticulum membrane, endoplasmic
reticulum anchored to the lumen side, Golgi
accumulation in the lumen, Golgi anchored to
the membrane on the lumen side, and plasma
membrane (Fig. 1, Table 1). Furthermore, addi-
tional strategies were considered to favor accu-
mulation of the Esat-6/Ag85b protein and thus
specific enrichment, including accumulation of
the target protein in the lumen of the endoplas-
mic reticulum by fusion with a zein domain, en-
richment and improved purification by fusion
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Figure 1. Target expression of the fusion protein in plant cell compartments. E.R., endoplasmic reticulum;
IgA, Immunoglobulin A.
Figure 2. Strategy for in vitro creation of the optimized synthetic fusion gene. Synthetic
optimized genes are created in vitro by recursive asymmetric PCR by annealing first long
primers 1 and 2, which are complementary over 15 nucleotides, and doing five cycles of
PCR. The first PCR product is, in turn, mixed with long primer 3, which also overlaps for 15
nucleotides, to yield PCR product after five cycles. This is repeated until addition of long primer
5. The final PCR product is cloned and sequenced prior to assembly with the other four blocks,
using restriction sites specifically engineered for that purpose. The full-length synthetic gene
is, in turn, sequenced and inserted in the various expression vectors using specific adapters.
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TABLE 1. Specific Components for Cell Compartment Targeting
System Promoter Targeting element Objective Reference
Chloroplast
expression
rrn promoter Chloroplast
transformation
vector
pZS197-JH1
Purification 15
Chloroplast rbcL
ribosome
binding site aadA
selectable marker
Cytoplasmic
production
35S promoter None Control
reference
16
Gelvin
“superpromoter”
Anchoring to
cytosolic side of
ER
Gelvin
“superpromoter”
Cyt. B5
transmembrane
domain
Purification 17
19 aa OP3 site
Transmembrane
domain I (ER)
35S promoter Lamp1
transmembrane
domain
Purification 18
TM17
Transmembrane
domain II (golgi)
35S promoter Lamp1
transmembrane
domain
Purification 18
TM20
Transmembrane
domain II
(plasma
membrane)
35S promoter Lamp1
transmembrane
domain
Purification 18
TM23
Elastin-like peptide
fusion
35S promoter ELP fusion peptide Enrichment 19
KDEL ER
retention signal
β-zein fusion 35S promoter Zein signal peptide Enrichment 20
Zein domain
Antibody–antigen
fusion
35S promoter IgA α2-α3 domains Enrichment 21,22
with an elastin polypeptide, and enrichment
and improved purification of the fusion protein
by fusion with an antibody (Table 1).
A Single Synthetic Transgene
Cassette Targeted to Several
Compartments
The selected transgene cassette is a fusion
gene comprising two genes Esat-6 and ag85b5
from M. tuberculosis and M. bovis. Early works
showed that effective vaccination could be
achieved with this fusion protein.7–9 Expression
of bacterial genes in plants often requires first
modifying and adapting the coding sequence to
that of the plant.10 A synthetic optimized gene
was thus created in vitro by recursive asymmetric
PCR method.11–14 The synthetic Esat-6/ag85b
fusion gene was assembled from four individ-
ual PCR-created blocks of 267 nucleotides (nt),
4
309 nt, 314 nt, and 314 nt, respectively (Fig. 2).
Targeting the protein to the various compart-
ments was achieved through the insertion of
transmembrane domains, targeting domains or
specific recombination vectors.
Concluding Remarks
Transient expression was achieved for all
constructs, and stable expression is currently
underway.However, owing to the time required
for stable plant transformation, line selection,
and selfing, no production can be expected
before an additional year. The availability of
stable transgenic lines will allow for final com-
parative assessment of the potential of each
compartment for the production of the same
antigen. Furthermore, the additional enrich-
ment strategies developed here will also pro-
vide information on the potential for increased
yield. Such research projects are long-term
projects requiring numerous subsequent steps,
and we are still far from the final outcome.
However, it was essential to introduce this novel
approach to the biannual Society for Tropical
Veterinary Medicine meeting owing to its im-
portant potential for human and animal health.
It is also a way to fill the gap between plant
and animal biotechnology and exemplify how
a global approach can be beneficial to every-
one. Finally, it is, to our knowledge, the first
time such a comprehensive genetic engineer-
ing strategy was developed to assess the influ-
ence of plant cell compartments on expression
of pharmaceutical proteins.
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